Showing results (211-220 of 379) with videos related to

Sort By:
Pageof 38
Lancet (London, England)|March 18, 2015
Worldwide access to treatment for end-stage kidney disease: a systematic reviewThaminda Liyanage, Toshiharu Ninomiya, Vivekanand Jha, et al.
European Journal of Heart Failure|June 27, 2024
Effects of canagliflozin on total heart failure events across the kidney function spectrum: Participant-level pooled analysis from the CANVAS Program and CREDENCE trialMuthiah Vaduganathan, Christopher P Cannon, Meg J Jardine, et al.
Journal of Renal Nutrition : the Official Journal of the Council on Renal Nutrition of the National Kidney Foundation|December 29, 2018
Dietary Sodium Reduction Reduces Albuminuria: A Cluster Randomized TrialMeg J Jardine, Nicole Li, Toshiharu Ninomiya, et al.
Circulation|August 21, 2023
Cardiorenal Biomarkers, Canagliflozin, and Outcomes in Diabetic Kidney Disease: The CREDENCE TrialJames L Januzzi, Reza Mohebi, Yuxi Liu, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|March 4, 2025
Effects of SGLT2 inhibition on insulin use in CKD and type 2 diabetes: Insights from the CREDENCE trialBryony Beal, Luke Buizen, Emily K Yeung, et al.
Circulation|June 27, 2018
Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney FunctionBrendon L Neuen, Toshiaki Ohkuma, Bruce Neal, et al.
Pageof 38